OncoSil Medical Ltd OSL
ASX · Australia · Health Technology
AUD 0.8300+0.01 (+1.22%)
Market open· · AUD · Data may be delayed
Prices may be delayed and are for informational purposes only - not investment advice.
Market open· · AUD · Data may be delayed
Prices may be delayed and are for informational purposes only - not investment advice.
Proceeds are earmarked for the commercial rollout of the OncoSil device in Australia and the US.
OncoSil Medical Ltd (ASX:OSL, OTC:OCMLF) has secured US Food and Drug Administration (FDA) approval for its OncoSil™ targeted radiation device to treat distal cholangiocarcinoma (dCCA), giving the company US marketing authorisation and opening an estimated A$80 million annual addressable...
The approval is expected to drive increased clinical adoption and support applications for regulatory approval in other markets.
Pancreatic cancer has long sat among oncology’s most difficult frontiers — a disease where survival rates remain stubbornly low, diagnoses often arrive too late and treatment breakthroughs have historically been limited. That backdrop helps explain why investors responded positively this week...
Recent third-party headlines about this company, kept separate from Makkler's own editorial coverage and linking out to the publisher. Accuracy is the publisher's responsibility.